Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis

详细信息    查看全文

• 作者：Hisao Nagoshi (1)
  Junya Kuroda (1)
  Tsutomu Kobayashi (1)
  Saori Maegawa (1)
  Yoshiaki Chinen (1)
  Miki Kiyota (1)
  Ryuko Nakayama (1)
  Shinsuke Mizutani (1)
  Yuji Shimura (1)
  Mio Yamamoto-Sugitani (1)
  Yosuke Matsumoto (1)
  Shigeo Horiike (1)
  Masafumi Taniwaki (1)
  
• 关键词：Angioimmunoblastic T ; cell lymphoma ; Plasmacytosis ; Polyclonal hyperglobulinemia ; Prognosis
• 刊名：International Journal of Hematology
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：98
• 期：3
• 页码：366-374
• 全文大小：503KB
• 参考文献：1. Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol. 2003;121:681鈥?1. CrossRef
  2. Iannitto E, Ferreri AJ, Minardi V, Tripodo C, Kreipe HH. Angioimmunoblastic T-cell lymphoma. Crit Rev Oncol Hematol. 2008;68:264鈥?1. CrossRef
  3. Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87:511鈥?. CrossRef
  4. Ren YL, Nong L, Zhang S, Zhao J, Zhang XM, Li T. Analysis of 142 Northern Chinese patients with peripheral T/NK-Cell lymphomas: subtype distribution, clinicopathologic features, and prognosis. Am J Clin Pathol. 2012;138:435鈥?7. CrossRef
  5. Kihara R, Watanabe T, Yano T, Uike N, Okamura S, Kawano F, et al. Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups. Int J Hematol. 2013;97:98鈥?02. CrossRef
  6. Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, et al. Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project. J Clin Oncol. 2013;31:240鈥?. CrossRef
  7. Tokunaga T, Shimada K, Yamamoto K, Chihara D, Ichihashi T, Oshima R, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood. 2012;119:2837鈥?3. CrossRef
  8. Mourad N, Mounier N, Bri猫re J, Raffoux E, Delmer A, Feller A, et al. Groupe d鈥橢tude des Lymphomes de l鈥橝dulte. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d鈥橢tude des Lymphomes de l鈥橝dulte (GELA) trials. Blood. 2008;111:4463鈥?0. CrossRef
  9. Hsu SM, Waldron JA Jr, Fink L, King C, Xie SS, Mansouri A, et al. Pathogenic significance of interleukin-6 in angioimmunoblastic lymphadenopathy-type T-cell lymphoma. Hum Pathol. 1993;24:126鈥?1. CrossRef
  10. Grogg KL, Morice WG, Macon WR. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol. 2007;137:416鈥?2. CrossRef
  11. Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490鈥?. CrossRef
  12. Iqbal J, Weisenburger DD, Greiner TC, Vose JM, McKeithan T, Kucuk C, International Peripheral T-Cell Lymphoma Project, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115:1026鈥?6. CrossRef
  13. Sekiguchi Y, Matsuzawa N, Shimada A, Imai H, Wakabayashi M, Sugimoto K, et al. Angioimmunoblastic T-cell lymphoma with intramedullary production of platelet-derived growth factor and possibly complicating myelofibrosis: report of a case with review of the literature. Int J Hematol. 2013 (in print).
  14. Attygalle AD, Chuang SS, Diss TC, Du MQ, Isaacson PG, Dogan A. Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics. Histopathology. 2007;50:498鈥?08. CrossRef
  15. Papadi B, Polski JM, Clarkson DR, Liu-Dumlao TO. Atypical angioimmunoblastic T-cell lymphomas masquerading as systemic polyclonal B-immunoblastic proliferation. Virchows Arch. 2012;461:323鈥?1. CrossRef
  16. Ahsanuddin AN, Brynes RK, Li S. Peripheral blood polyclonal plasmacytosis mimicking plasma cell leukemia in patients with angioimmunoblastic T-cell lymphoma: report of 3 cases and review of the literature. Int J Clin Exp Pathol. 2011;4:416鈥?0.
  17. Sakai H, Tanaka H, Katsurada T, Yoshida Y, Okamoto E, Ohno H. Angioimmunoblastic T-cell lymphoma initially presenting with replacement of bone marrow and peripheral plasmacytosis. Intern Med. 2007;46:419鈥?4. CrossRef
  18. Yamane A, Awaya N, Shimizu T, Ikeda Y, Okamoto S. Angioimmunoblastic T-cell lymphoma with polyclonal proliferation of plasma cells in peripheral blood and marrow. Acta Haematol. 2007;117:74鈥?. CrossRef
  19. Kobayashi T, Kuroda J, Uchiyama H, Matsumoto Y, Horiike S, Taniwaki M. Successful treatment of chemotherapy-refractory angioimmunoblastic T cell lymphoma with cyclosporin A. Acta Haematol. 2012;127:10鈥?. CrossRef
  20. Matsumura Y, Kuroda J, Shimura Y, Kiyota M, Yamamoto-Sugitani M, Kobayashi T, et al. Cyclosporine A and reduced-intensity conditioning allogeneic stem cell transplantation for relapsed angioimmunoblastic T cell lymphoma with hemophagocytic syndrome. Intern Med. 2012;51:2785鈥?.
  21. The International Non-Hodgkin鈥檚 Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin鈥檚 lymphoma. N Engl J Med. 1993;329:987鈥?4. CrossRef
  22. Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Intergruppo Italiano Linfomi, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474鈥?. CrossRef
  23. Fern谩ndez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780鈥?1. CrossRef
  24. Pellat-Deceunynck C, Bataille R. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis. 2004;32:293鈥?01. CrossRef
  25. Jego G, Robillard N, Puthier D, Amiot M, Accard F, Pineau D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood. 1999;94:701鈥?2.
  26. Li L, Hsu P, Patel K, Saffari Y, Ashley I, Brody J. Polyclonal plasma cell proliferation with marked hypergammaglobulinemia and multiple autoantibodies. Ann Clin Lab Sci. 2006;36:479鈥?4.
  27. Ebara S, Song SN, Mizuta H, Ito Y, Hasegawa K, Kamata T, et al. Interleukin-6-producing dermoid cyst associated with multicentric Castleman鈥檚 disease. Int J Hematol. 2012;95:198鈥?03. CrossRef
  28. Advani R, Horwitz S, Zelenetz A, Horning SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma. 2007;48:521鈥?. CrossRef
  
• 作者单位：Hisao Nagoshi (1)
  Junya Kuroda (1)
  Tsutomu Kobayashi (1)
  Saori Maegawa (1)
  Yoshiaki Chinen (1)
  Miki Kiyota (1)
  Ryuko Nakayama (1)
  Shinsuke Mizutani (1)
  Yuji Shimura (1)
  Mio Yamamoto-Sugitani (1)
  Yosuke Matsumoto (1)
  Shigeo Horiike (1)
  Masafumi Taniwaki (1)
  
  1. Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan
  

文摘

Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of non-Hodgkin lymphoma characterized by aggressive symptoms and various abnormal laboratory test results. One of the rare immunologic abnormalities in AITL is exuberant polyclonal plasmacytosis, but its clinical significance has not been evaluated. This report concerns three AITL cases with exuberant polyclonal plasmacytosis and investigates its clinical impact by comparison with 12 patients without plasmacytosis. Our study found that the performance status (PS) of the former was significantly worse and their serum immunoglobulin levels were significantly higher. All other parameters, including B symptoms, various prognostic scores, blood cell counts other than plasmacyte, and serum levels of lactate dehydrogenase, C-reactive protein and soluble interleukin-2 receptor, showed no significant differences. More importantly, although the diagnosis of AITL with plasmacytosis was not straightforward in our series, outcomes of treatment with conventional chemotherapy or immunosuppressive therapy with cyclosporine A were favorable. To conclude, AITL should be considered a candidate underlying disease of exuberant polyclonal plasmacytosis. Provided a correct diagnosis is made early and is followed by adequate treatment, the prognosis for AITL with plasmacytosis may not be worse than that for those without plasmacytosis despite the severe exhaustion at first presentation.